What is Dogwood Therapeutics's goodwill?

Dogwood Therapeutics (DWTX) reported goodwill of $12.19M in Q1 2026.

How has Dogwood Therapeutics's goodwill changed year-over-year?

Dogwood Therapeutics's goodwill increased by 3.1% year-over-year, from $11.82M to $12.19M.

What does goodwill mean?

The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.

Dogwood Therapeutics DWTX Goodwill

Goodwill at other companies

Eli LillyLLY

$6.13B+6.2%

PfizerPFE

$71.41B+4.3%

Vertex PharmaceuticalsVRTX

$1.09B0.0%

Collegium Pharmaceutical, Inc.COLL

$145.93M-3.2%

BioventusBVS

$7.46M0.0%

Avanos MedicalAVNS

$394M-13.6%

Other financials

Income statement

See full

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Balance sheet

See full

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Cash flow

See full

Operating cash flow-$4.6M+2.0%

Valuation

See full

Market cap$54.14M-57.6%

Enterprise value$41.06M-64.7%

Returns & leverage

See full

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dogwood Therapeutics's goodwill?: Dogwood Therapeutics (DWTX) reported goodwill of $12.19M in Q1 2026.
How has Dogwood Therapeutics's goodwill changed year-over-year?: Dogwood Therapeutics's goodwill increased by 3.1% year-over-year, from $11.82M to $12.19M.
What does goodwill mean?: The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.